Recombinant Human Erythropoietin Dose, Serum Adiponectin, and All-Cause Mortality in Patients Beginning Hemodialysis
Decreased body fat mass, possibly mediated through the effects of elevated serum adiponectin levels, may be associated with requirements for higher recombinant human erythropoietin doses and a subsequent worse prognosis in patients beginning hemodialysis.
|Study Design:||Observational Model: Defined Population
Time Perspective: Longitudinal
Please refer to this study by its ClinicalTrials.gov identifier: NCT00457561
|Principal Investigator:||Naro Ohashi, MD,PhD||First Department of Medicine, Hamamatsu University School of Medicine|